• Publications
  • Influence
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results
The combined clinimetric results of this study support the validity of the MDS‐UPDRS for rating PD. Expand
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Exper experiences of daily Living; III, Motor Examination; and IV, Motor Complications. Expand
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo. Expand
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
The efficacy and safety of bilateral infusion of AAV2-GAD in the subthalamic nucleus supports its further development for Parkinson's disease and shows the promise for gene therapy for neurological disorders. Expand
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Initial treatment with pramipexole resulted in lower incidences of freezing, somnolence, and edema and provided for better symptomatic control, as measured by the Unified Parkinson's Disease Rating Scale, compared with initial treatment with levodopa, which resulted in similar quality of life. Expand
Advanced Parkinson disease treated with rotigotine transdermal system
Transdermal rotigotine significantly improved “off” time in subjects with Parkinson disease not optimally controlled with levodopa and was safe and well tolerated, with typical dopaminergic side effects and occasional application site reactions. Expand
Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions
The altered relationship between iron and transferrin provides further evidence that a disturbance in iron metabolism may be involved in both Alzheimer's and Parkinson's disease. Expand
Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment
This study compares the sensitivity of a Patient Questionnaire versus information gathered by clinicians at a routine clinic visit in recognizing symptoms of wearing‐off in early Parkinson's diseaseExpand
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
  • P. Lewitt
  • Medicine
  • Movement disorders : official journal of the…
  • 1 January 2015
Several new pharmaceutical approaches are targeted at the unique physiology of l‐dopa uptake and are likely to improve the consistency of its anti‐Parkinsonian effect. Expand
Levodopa in the treatment of Parkinson's disease: Current controversies
Treatment strategies that provide more continuous stimulation of dopamine receptors provide reduced motor complications in MPTP monkeys and PD patients and studies raise the possibility that more continuous and physiological delivery of levodopa might reduce the risk of motor complications. Expand